Casdatifan shows durable response linked to HIF-2α biology in kidney cancer

  • Choueiri, Toni K.; 
  • Merchan, Jamie; 
  • Patnaik, Amita; 
  • Drakaki, Alexandra; 
  • Rini, Brian I.; 
  • ... Park, Se Hoon; 
  • 외 20명
Citations

WEB OF SCIENCE

2
Citations

SCOPUS

1

초록

Clear cell renal cell carcinoma (ccRCC) is largely driven by the transcription factor hypoxia-inducible factor 2 alpha (HIF-2 alpha)1. Here we show that monotherapy with casdatifan-an orally bioavailable, potent and selective HIF-2 alpha inhibitor2-produces meaningful, durable antitumour activity with manageable safety in individuals with refractory metastatic ccRCC. Dose-expansion data from the ARC-20 study (NCT05536141) are presented, including for the 100 mg once daily (QD) cohort (n = 32) and the total cohort (n = 127). Treatment discontinuation from casdatifan-related adverse events was infrequent (3%), and class-effect toxicities included anaemia and hypoxia. The confirmed objective response rates (ORRs) were 35% (95% confidence intervals (CI) = 19-55%; 100 mg QD) and 31% (95% CI = 23-40%; total); median progression-free survival (PFS) was not estimable (95% CI = 5.7-not estimable; 100 mg QD) and 12.2 months (9.4-20.6; total). Greater maximal reductions in serum erythropoietin were associated with improved clinical outcomes, including a higher ORR (P = 0.001), lower rates of progressive disease (P = 0.003) and longer PFS (P = 0.006). Erythropoietin expression was restricted to cancer cells and was significantly higher at the mRNA level in patients with clinical benefit. Concordantly, HIF-2 alpha protein expression and HIF-2 alpha expression signature were associated with prolonged PFS. Overall, our findings show that casdatifan achieves meaningful, durable responses with manageable safety. These data establish a link between on-target HIF-2 alpha pathway modulation, tumour biology and clinical efficacy.

키워드

RENAL-CELL CARCINOMA; DOSE-ESCALATION; HYPOXIA; ANTAGONIST; AB521
제목
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer
저자
Choueiri, Toni K.; Merchan, Jamie; Patnaik, Amita; Drakaki, Alexandra; Rini, Brian I.; Rha, Sun Young; Lee, Jae Lyun; Ornstein, Moshe C.; Kumar, Rohit; Hwang, Clara; Shao, Yusra; Park, Se Hoon; Barata, Pedro C.; McGregor, Bradley A.; Foster, Paul; Chen, Jianfen; Eisen, Melissa; Cole, Hunter; Weeder, Ben; Guan, Yinghui; Singh, Jaskirat; Kaplan, Angelo; Cho, Soonweng; Markus, Richard; Kabbarah, Omar; McKay, Rana R.
DOI
10.1038/s41586-026-10718-x
발행일
2026-08
유형
Article
저널명
Nature
권
656
호
8128
페이지
734 ~ 741